Hong I. Wan, Ph.D., Scientific Advisor

Hong I. Wan, Ph.D. is president, chief executive officer and co-founder of Tallac Therapeutics. Previously as chief scientific officer and a member of the founding management at ALX Oncology, she led the team to advance ALX148, a best-in-class myeloid checkpoint inhibitor, for multiple tumor indications. Prior to ALX Oncology, Dr. Wan held various leadership positions at Pfizer and Wyeth Research, where she was responsible for the early development and translational medicine strategy and execution across various therapeutic areas. Dr. Wan started her career at Renovis where she led discovery programs in neuroinflammation.

Education:

Ph.D. in Molecular and Cell Biology from University of California, Berkeley
A.B. in Biochemical Sciences from Harvard University

Sector: Biopharmaceuticals

Location: Menlo Park

 
See other team members.